Obtenga las últimas noticias sobre las acciones de Rein Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de RNTX

Últimas noticias sobre

REIN THERAPEUTICS INC

Rein Therapeutics

Aileron Therapeutics

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Konskie,,Poland,-,March,08,,2025:,Restoration,Hardware,Company,Logo

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADBE

BIAF

CGBS

EONR

FGEN

GNLN

HCTI

HUSA

INDO

NINE

PRZO

RNTX

RSLS

SBET

TPET

TRAW

USEG

VEON

RH sorprende con ganancias positivas en el primer trimestre y mantiene su guía para 2025, mientras sus acciones suben un 18,2 %.

Las acciones de RH se disparan un 18%; Aquí están 20 acciones que se mueven antes de la apertura del mercado

Rein Therapeutics Inc

Earnings

Press Releases

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Financing

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Health Care

General

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Analyst Ratings

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

ENTA

AlphaTON Capital

Boundless Bio

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

LAVA Therapeutics

Mural Oncology

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Pluri

Q32 Bio

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

RenovoRx

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tenax Therapeutics

Exicure

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

HC Wainwright & Co.

Comments

Rein Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL